SCHEMBL5714729

SCHEMBL5714729

O=C(Oc1ccc(CCSc2ccncc2)cc1)N1CCN(c2ccc(F)cn2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ME2 P23368 6/20 0.46
ME1 P48163 6/20 0.46
ME3 Q16798 6/20 0.46
PANK3 Q9H999 1/20 0.42
HRH3 Q9Y5N1 2/20 0.42
TRPV1 Q8NER1 2/20 0.40
CHRM1 P11229 1/20 0.40
GPR119 Q8TDV5 1/20 0.40
ALOX15 P16050 1/20 0.40
DRD2 P14416 1/20 0.39
DRD1 P21728 1/20 0.39
DRD5 P21918 1/20 0.39
DRD3 P35462 1/20 0.39
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TRPA1 O75762 1/20 0.38
PRKAA2 P54646 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715446 0.89 PANK3 (0.44) ME2ME1ME3PANK3HRH3
SCHEMBL5714517 0.89 ME2 (0.46) ME2ME1ME3PANK3TRPV1
SCHEMBL5714344 0.88 SMN1; SMN2 (0.54) TRPV1HPGDSMN1; SMN2TRPA1MEN1
SCHEMBL5714815 0.88 HRH3 (0.42) ME2ME1ME3PANK3HRH3
SCHEMBL5714635 0.88 PANK3 (0.42) ME2ME1ME3PANK3TRPV1
SCHEMBL5714477 0.88 ME2 (0.50) ME2ME1ME3PANK3HRH3
SCHEMBL5715128 0.86 ME2 (0.43) ME2ME1ME3PANK3HRH3
SCHEMBL5715233 0.86 ME2 (0.45) ME2ME1ME3PANK3HRH3
SCHEMBL5714398 0.86 ALDH1A1 (0.52) TRPV1HPGDSMN1; SMN2MEN1ALDH1A1
SCHEMBL5715416 0.84 ME2 (0.43) ME2ME1ME3PANK3HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN disclosed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC ME2 854/4885ME1 2914/4885ME3 1308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.